CN115361973A - 神经炎症的抑制、用于抑制神经炎症的组合物以及方法 - Google Patents

神经炎症的抑制、用于抑制神经炎症的组合物以及方法 Download PDF

Info

Publication number
CN115361973A
CN115361973A CN202180026757.6A CN202180026757A CN115361973A CN 115361973 A CN115361973 A CN 115361973A CN 202180026757 A CN202180026757 A CN 202180026757A CN 115361973 A CN115361973 A CN 115361973A
Authority
CN
China
Prior art keywords
cells
pharmaceutical composition
neuroinflammation
present disclosure
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180026757.6A
Other languages
English (en)
Chinese (zh)
Inventor
萩原正敏
小林亚希子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of CN115361973A publication Critical patent/CN115361973A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180026757.6A 2020-04-01 2021-03-31 神经炎症的抑制、用于抑制神经炎症的组合物以及方法 Pending CN115361973A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020066150 2020-04-01
JP2020-066150 2020-04-01
PCT/JP2021/014030 WO2021201171A1 (ja) 2020-04-01 2021-03-31 神経炎症の抑制、そのための組成物及び方法

Publications (1)

Publication Number Publication Date
CN115361973A true CN115361973A (zh) 2022-11-18

Family

ID=77929171

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026757.6A Pending CN115361973A (zh) 2020-04-01 2021-03-31 神经炎症的抑制、用于抑制神经炎症的组合物以及方法

Country Status (5)

Country Link
US (1) US12605368B2 (https=)
EP (1) EP4129340B1 (https=)
JP (1) JP7699831B2 (https=)
CN (1) CN115361973A (https=)
WO (1) WO2021201171A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745323B2 (en) 2012-07-30 2017-08-29 Kyoto University Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
CA2912345C (en) 2013-05-16 2020-10-06 Sumitomo Dainippon Pharma Co., Ltd. Transplantation adjuvant in cell therapy using neural progenitor cells
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
WO2015107945A1 (ja) 2014-01-17 2015-07-23 ソニー株式会社 スイッチ素子および記憶装置
CN106535890A (zh) 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
WO2018029793A1 (ja) 2016-08-09 2018-02-15 株式会社Ａｏｂ慧央グループ Ｉｌ－６産生抑制剤、抗炎症剤、抗神経変性疾患剤、抗精神神経疾患剤、医薬品及び食品
WO2018043674A1 (ja) 2016-08-31 2018-03-08 国立大学法人京都大学 神経新生を活性化するための組成物
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof

Also Published As

Publication number Publication date
JPWO2021201171A1 (https=) 2021-10-07
US20230117374A1 (en) 2023-04-20
EP4129340A1 (en) 2023-02-08
EP4129340A4 (en) 2024-08-07
US12605368B2 (en) 2026-04-21
EP4129340B1 (en) 2025-12-03
WO2021201171A1 (ja) 2021-10-07
JP7699831B2 (ja) 2025-06-30

Similar Documents

Publication Publication Date Title
US20180055887A1 (en) Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications
CN109073634B (zh) 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
Bahlakeh et al. Neurotrophic factor-secreting cells restored endogenous hippocampal neurogenesis through the Wnt/β-catenin signaling pathway in AD model mice
US9028810B2 (en) Composition for inducing migration of neural stem cells containing periostin as effective ingredient
US11946070B2 (en) Method of reinforcing efficacy of stem cells using ethionamide
JP2003535062A (ja) Ｊｎｋ阻害剤としての（二置換フェニル）ピリミジニルイミダゾール誘導体の使用
US20250257324A1 (en) Extracellular vesicles isolated from mesenchymal stem cells derived from chemically-induced pluripotent stem cells, and use thereof
WO2016035934A1 (ko) Gm1 강글리오시드증의 인간 세포 모델 및 이의 용도
US9499787B2 (en) Method for differentiating stem cells into neurons
WO2013012269A2 (ko) 전능성 줄기세포로부터 희소돌기아교 전구세포의 제조 방법
US20180280447A1 (en) Placenta-derived cells excreting c3 or c1r complement and composition containing same
CN115361973A (zh) 神经炎症的抑制、用于抑制神经炎症的组合物以及方法
EP4387622B1 (en) Haloperidol for use in the treatment of spinal muscular atrophy
WO2020141648A1 (ko) 체세포로부터 분화된 신규한 유사신경교세포, 이의 제조 방법, 이의 제조용 칵테일 조성물, 이를 포함하는 신경 질환 예방 또는 치료용 세포 치료제 및 이를 투여하여 신경 질환을 예방 및 치료하는 방법
KR101862548B1 (ko) 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
KR101948247B1 (ko) Oct4 저해용 조성물 및 이의 용도
KR20260032533A (ko) 세포 재프로그래밍
KR101833412B1 (ko) 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
US20210145838A1 (en) Selective pde4d inhibitors against demyelinating diseases
WO2026089592A1 (ko) 신장 질환의 예방 또는 치료용 조성물
KR100818191B1 (ko) 베타아밀로이드 펩타이드에 의한 간엽 줄기세포의 신경분화유도방법
WO2015080376A1 (ko) 태반의 융모막 또는 와튼제대교질 유래 간엽줄기세포로부터 신경세포 및 유모세포를 분화시키는 방법
HK1262420B (en) Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition
HK1262420A1 (en) Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination